AtaiBeckley’s investigational drug BPL-003 has demonstrated promising results in treating depression that persists despite SSRI therapy. A Phase 2a trial published in CNS Drugs showed a 66.7% response rate by Day 2 with a single intranasal dose of BPL-003, maintained through Week 12 in the 10 mg cohort. The study provides the first Phase 2a evidence that BPL-003 can be administered alongside SSRIs without compromising efficacy or safety—a meaningful advance for the estimated 30% of depression patients globally with treatment-resistant depression.
Study Design and Results
The 12-week open-label trial enrolled 12 adults aged 18 to 75 years with moderate-to-severe major depressive disorder (baseline MADRS score of 24 or higher) and treatment-resistant depression. All participants had failed at least two prior antidepressants and remained on a stable dose of one of four SSRIs—citalopram, escitalopram, sertraline, or fluoxetine. Six participants received a single intranasal 10 mg dose of BPL-003 and six received a single intranasal 12 mg dose, with psychological support before, during, and after dosing. Part 1 of the four-part Phase 2a study, published in the Journal of Psychopharmacology in March 2026, reported a mean 12.6-point MADRS reduction by Day 2, sustained through 12 weeks. Part 3 topline data, announced in September 2025, showed that a second dose at Week 2 has the potential to induce additional MADRS reductions without impact on safety and tolerability.
Clinical Implications
According to Dr. Kevin Craig, Chief Medical Officer at AtaiBeckley, rapid resolution of acute effects and approximately 100-minute discharge readiness “further support the feasibility of integrating BPL-003 into existing interventional psychiatry settings.” BPL-003 has been granted Breakthrough Therapy designation by the FDA and is covered by granted U.S., U.K., and European composition-of-matter patents. The company plans to initiate Phase 3 trials in Q2 2026, with Part 4 data on a two-dose induction regimen expected in Q4 2026.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110956527/Ataibeckleys-BPL-003-Shows-Rapid-Durable-Antidepressant-Response-In-Treatment-Resistant-Depression-Patients-On-Ssris-Phase-2A-Data-Published-In-CNS-Drugs